|1.||Jones, Ronald N: 8 articles (02/2012 - 09/2002)|
|2.||Nicholson, Susan C: 8 articles (09/2002 - 06/2002)|
|3.||Dolecek, Christiane: 6 articles (04/2015 - 01/2007)|
|4.||Mah, Francis S: 6 articles (01/2011 - 09/2003)|
|5.||Basnyat, Buddha: 5 articles (04/2015 - 01/2007)|
|6.||Jensen, Harold: 5 articles (12/2014 - 09/2003)|
|7.||Moshirfar, Majid: 5 articles (10/2008 - 03/2006)|
|8.||Romanowski, Eric G: 5 articles (08/2008 - 09/2003)|
|9.||Gordon, Y Jerold: 5 articles (08/2008 - 09/2003)|
|10.||Kowalski, Regis P: 5 articles (08/2008 - 09/2003)|
11/01/1997 - "These results suggest that the clinical efficacy of AM-1155 against infections involving most anaerobic bacteria except for the B. "
06/01/2002 - "The magnitude of the 24-h AUC/MIC of gatifloxacin required for efficacy against multiple pathogens varied only fourfold and was not significantly altered by drug resistance or site of infection."
08/18/2008 - "The results indicated that gatifloxacin is still effective against MRSA isolates and might be useful for treatment of less serious MRSA infections but careful monitoring of susceptibility is required."
03/01/2005 - "Gatifloxacin is an 8-methoxy fluoroquinolone effective against a broad spectrum of pathogens common in pediatric infections. "
01/01/2001 - "Gatifloxacin should prove to be a safe and effective agent for a wide variety of infections."
09/01/2002 - "To evaluate the safety and efficacy of gatifloxacin in adults <65, 65 to 79, or > or =80 years old with community-acquired pneumonia, adult male and female outpatients from general community-based practices were enrolled in an open-label, multicenter, noncomparative study. "
09/01/2004 - "In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants."
09/01/2002 - "Gatifloxacin is an advanced-generation fluoroquinolone with demonstrated efficacy and safety as therapy for community-acquired pneumonia (CAP). "
10/01/2007 - "To consider the optimized administration method based on PK/PD theory for the elderly patients of gatifloxacin (GFLX), which was one of the oral respiratory quinolone antibacterial, Monte Carlo Simulation was conducted with community-acquired pneumonia and susceptibility data for Streptococcus pneumoniae (345 strains) collected by the second gatifloxacin surveillance study. "
02/01/2003 - "An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers."
11/01/2013 - "Gatifloxacin 0.3% ophthalmic solution due to its strong activity against various gram-positive and gram-negative microbes is strongly effective in the treatment of acute bacterial keratitis."
04/01/2010 - "Topical gatifloxacin 0.3% may be successfully used to treat microbial keratitis resulting from atypical mycobacteria."
06/01/2007 - "Zymar may prove useful for SM and PA keratitis."
07/01/2005 - "The fourth-generation fluoroquinolone, gatifloxacin, could be effectively used for the treatment of mycobacterial keratitis."
08/01/2004 - " Relevance Topical gatifloxacin 0.3% may provide an initial alternative in therapy of M chelonae keratitis."
|4.||Urinary Tract Infections (Urinary Tract Infection)
10/01/1992 - "AM-1155 also had good efficacy against mouse ascending urinary tract infections with Escherichia coli and P. "
03/01/2000 - "These results suggest that gatifloxacin may be useful in the treatment of urinary tract infections."
04/01/2009 - "To assess the clinical efficacy of oral antibiotic administration for the treatment of lower urinary tract infection (UTI), 102 female patients were given gatifloxacin (200 mg once daily for 3 days). "
08/01/2006 - "Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice."
03/01/2006 - "A 48-year-old man participating in a residential treatment program was treated with gatifloxacin for a urinary tract infection. "
03/01/2003 - "The results of the study show that gatifloxacin is a safe and effective agent for the treatment of patients with chronic bronchitis experiencing an acute infectious exacerbation."
01/01/2007 - "Based on the findings of this study in small numbers of healthy young adult volunteers and patients with chronic bronchitis, BMS appears to be a promising method for measuring drug concentrations and determining the pharmacokinetic profile of gatifloxacin in bronchial ELF. "
01/01/2007 - "Bronchial ELF samples were obtained by BMS at 1, 2, 3, 4, 6, 10, and 24 hours after administration of a single oral dose of gatifloxacin 200 mg in healthy young adult (aged 20-25 years) subjects, and at 1, 2, 4, and 10 hours after a single dose in patients with chronic bronchitis (aged > or =20 years). "
01/01/2007 - "BMS and BAL were used to analyze the pharmacokinetics of gatifloxacin in bronchial ELF from healthy young adult subjects and adult patients with chronic bronchitis. "
01/01/2007 - "Pharmacokinetics of gatifloxacin after a single oral dose in healthy young adult subjects and adult patients with chronic bronchitis, with a comparison of drug concentrations obtained by bronchoscopic microsampling and bronchoalveolar lavage."
|8.||Clavulanic Acid (Potassium Clavulanate)
|2.||Laser In Situ Keratomileusis (LASIK)
|4.||Dry Powder Inhalers